Inotuzumab ozogamicin (Besponsa) is a key therapeutic agent for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia, exerting its therapeutic effect through precise targeting of the CD22 antigen.

Precautions for Inotuzumab ozogamicin (Besponsa) Administration

Strict Adherence to Prescribed Dosage Regimen

The recommended total dose for Cycle 1 is 1.5 mg/m².

For subsequent cycles, the dose is adjusted to 1.5 mg/m² or 1.8 mg/m² based on whether the patient achieves Complete Remission (CR) or Complete Remission with incomplete hematologic recovery (CRi), with a cycle length of 28 days.

Premedication Requirements

Premedication is mandatory before each dose, including corticosteroids, antipyretic analgesics, and antihistamines.

For patients with circulating lymphoblasts, cytoreduction with hydroxyurea, steroids, and/or vincristine is recommended prior to the first dose.

Monitoring During Inotuzumab ozogamicin (Besponsa) Administration

Focused Liver Function Monitoring

Closely monitor for signs and symptoms of Veno-Occlusive Disease (VOD), including: elevated total bilirubin, hepatomegaly with pain, rapid weight gain, and ascites.

Assess liver function parameters (ALT, AST, total bilirubin, alkaline phosphatase) before treatment initiation and after each dose.

For patients scheduled to undergo Hematopoietic Stem Cell Transplantation (HSCT), monitor liver function at least weekly during the first month post-treatment.

Hematologic Toxicity Monitoring

Myelosuppression is a common adverse reaction, including thrombocytopenia and neutropenia.

Perform a complete blood count before each dose, and monitor for signs and symptoms of infection, bleeding/hemorrhage, or other effects of myelosuppression.

When appropriate, administer prophylactic anti-infective agents and conduct surveillance testing during and after treatment.

Electrocardiogram (ECG) and Electrolyte Monitoring

This medication may prolong the QTc interval.

Obtain a baseline ECG and electrolyte levels before treatment, and monitor periodically during treatment.

Infusion Reaction Monitoring

Closely monitor patients during the infusion and for at least 1 hour after completion of the infusion.

If an infusion-related reaction occurs, interrupt the infusion and initiate appropriate medical management.

Permanent discontinuation of the medication is mandatory for severe or life-threatening infusion reactions.